CN102302147A - 多肽解酒醒酒饮料 - Google Patents
多肽解酒醒酒饮料 Download PDFInfo
- Publication number
- CN102302147A CN102302147A CN201110165891A CN201110165891A CN102302147A CN 102302147 A CN102302147 A CN 102302147A CN 201110165891 A CN201110165891 A CN 201110165891A CN 201110165891 A CN201110165891 A CN 201110165891A CN 102302147 A CN102302147 A CN 102302147A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- kilograms
- glutathione
- beverage
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 18
- 235000013361 beverage Nutrition 0.000 title claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 7
- 229920001184 polypeptide Polymers 0.000 title claims description 4
- 230000000694 effects Effects 0.000 title abstract description 11
- 235000013334 alcoholic beverage Nutrition 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 31
- 108010024636 Glutathione Proteins 0.000 claims abstract description 15
- 229960003180 glutathione Drugs 0.000 claims abstract description 15
- 230000001954 sterilising effect Effects 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 235000012907 honey Nutrition 0.000 claims abstract description 7
- 238000011049 filling Methods 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 238000012360 testing method Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 44
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 21
- 229930003268 Vitamin C Natural products 0.000 abstract description 21
- 235000019154 vitamin C Nutrition 0.000 abstract description 21
- 239000011718 vitamin C Substances 0.000 abstract description 21
- 210000004185 liver Anatomy 0.000 abstract description 14
- 230000036772 blood pressure Effects 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 2
- 235000020510 functional beverage Nutrition 0.000 abstract 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 2
- 235000019158 vitamin B6 Nutrition 0.000 abstract 2
- 239000011726 vitamin B6 Substances 0.000 abstract 2
- 229940011671 vitamin b6 Drugs 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 10
- 238000011160 research Methods 0.000 description 8
- 208000007848 Alcoholism Diseases 0.000 description 7
- 208000001953 Hypotension Diseases 0.000 description 7
- 201000007930 alcohol dependence Diseases 0.000 description 7
- 208000021822 hypotensive Diseases 0.000 description 7
- 230000001077 hypotensive effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000035622 drinking Effects 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 241000209094 Oryza Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229940124277 aminobutyric acid Drugs 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical class CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000036445 liquid secretion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于功能饮料,尤其以醒酒肽,谷胱甘肽,y—氨基酸、蜂蜜、维生素C,维生素B6,辅料制成的功能饮料。该产品的制作工艺为:调配混合,溶解搅拌,过滤,灌装封盖,杀菌,检验合格成为正式产品。本产品含有醒酒肽、谷胱甘肽、y—氨基丁酸,蜂蜜、维生素C、维生素B6等原料。具有解酒醒酒、保护肝脏、降血压、增强免疫力等功能。
Description
一、技术领域:本发明属于功能饮料,尤以醒酒肽、谷胱甘肽、氨基丁酸、维生素C、维生素B6、蜂蜜等原料,采取先进工艺加工而成的功能饮料。
二、背景技术:该发明以醒酒肽、谷胱甘肽、氨基丁酸、维生素C、维生素B6、蜂蜜等加工而成的功能饮料。该产品具有解酒、醒酒、保肝脏、降血压、增强免疫力等功能。目前市场上还没有同类功能产品出现,研制该产品可为给酗酒者提供一种新型的功能饮料。
三、发明内容:珍爱生命,保护健康,少量饮酒。随着我国经济的快速发展,国民的生活水平不断提高,人们的社交活动日益频繁,对酒的消费量迅速上升,因此,给健康也带来很大的隐患。大量的研究表明,长期饮酒可导致机体各系统损伤、精神障碍、认知功能阳碍。酗酒及其所导致的营养失衡,是慢性疾病发生的主要影响之一。如酒精性肝损伤是长期大量饮酒所造成的伤害,发展为慢性肝炎,最后转为肝硬化,少数可恶化为肝癌等。据日本研究证实,女性过量饮酒会增加患乳腺癌的风险。法国一项最新研究发现,狂饮酒者心脏病的发病率会增加一倍。据统计我国每年有数十万人过量饮酒而死亡,另有数十万人死于酗酒导致的交通或其他事故中。
四、原料配方:醒酒肽40—60千克,谷胱甘肽4—6千克,氨基丁酸6—8千克,维生素C3—5千克,维生素B60.2—0.5千克,蜂蜜8—10千克,辅料。
五、技术方案
(一)醒酒肽:多肽是一类由氨基酸组成的比蛋白质小却具有营养和调节功能的小分子化合物。是涉及人体生物各种细胞功能的生物活性物质,分子小具有生物活性,所以能防治多种疾病,如解酒醒酒、护肝、肥胖、糖尿病、心血管、高血脂、高血压、冠心病等。
生理功能:1、解酒护肝:研究表明,醒酒肽具有显著的降低血液中的乙醇浓度的功效,促进乙醇清除,消除酒后产生的过量自由基,阻碍过氧化脂质形成,避免酒精中毒导致的各种代谢导常,从而减轻乙醇对肝组织的损伤,因此,醒酒肽对酒后解酒、醒酒、护肝具有显著的作用。另据报道,醒酒肽可与酒精发生凝聚反应,可凝聚的部分酒精,减缓吸收。
2、降血压:醒酒肽可以有效的抑制使血压升高的血管紧张素转换酶,从而达到降低血压或使血压不升高的目的,因此具有降血压功能。
(二)谷胱甘肽(GSH)谷胱甘肽是一种具有重要生理功能的活性三肽,由谷氨酸、半胱氨基和甘氨酸通过肽键缩合而成的三肽化合物,其功能用途广泛。但只有还原型谷胱甘肽才具有生物活性。科学研究认为,谷胱甘肽具有抗氧化,增强免疫力、解酒毒护肝、清除自由基、延缓衰老、抗辐射、抗癌等功能。
生理功能:1、抗氧化:谷胱甘肽含有活泼的SH,能将人体细胞新陈代谢生成的H2O2,能清除人体的自由基。自由基会损伤人体细胞膜,促进机体衰老,并诱发癌症和动脉硬化。谷胱甘肽具有防治人体细胞过氧化作用。
2、解酒毒护肝:谷胱甘肽能改善酒精所导致的各种代谢导常。可保护胃黏膜免受乙醇的伤害,增强肝脏的解毒作用,从而有效预防酒醉出现的头痛、呕吐、恶心及缩酒等症状。还可以保护和修复肝细胞膜加速肝脏对毒物的分解代谢,对抗乙醇及乙醛对肝的损害。另据报道,谷胱甘肽具有广谱的解毒作用,对机体的有毒化合物和致癌物质等相结合,并促进排出体外,也可用于中毒症的治疗。谷肽甘肽对重金属也有解毒作用,具有保护肝脏,防止脂肪肝形成,还可作为护肝剂。
(三)y—氨基丁酸(GABA)又名氨酪酸。是一种天然存在的非蛋白氨基酸;是谷氨酸脱羧酶催化转化产生。在自然界微量存在于哺乳动物脑髓和植物的胚芽体内。人体自身能合成,y—氨基丁酸,但在y—氨基丁酸丙酮转氨酶的作用下,y—氨基丁酸会降解。国内外科学研究发现,y—氨基丁酸能通过中枢神经系统,促进血管扩张,具有健脑益智、镇静神经、改善胃肠道、降血压、解酒、活化肝功能、延缓衰老、改善更年期综合症等多种生理功能。
生理功能:1、解酒毒:据报道,日本釜山大学研究发现,把含有氨基丁酸的大米在玄米状态下喂鼠显示酒精中毒症状的老鼠时,发现酒精摄入量减少50%左右,以发芽米的状态食用该大米的老鼠,其酒精摄入量减少了65%,研究者称,氨基丁酸含量越高,酒精摄入量越少。
2、降血压:氨基丁酸可作用于延髓的血管运动中枢,同时抑制抗利尿激素后叶加压素的分泌,能扩张血管,从而使血压下降。
(五)维生素C(Vitc)又名抗坏血酸,广泛存在于水果和蔬菜中的天然物质。维生素是一种简单的六碳化合物,自然界有两种存在形式,均可被机体利用。维生素C为白色结晶粉末,带有明显的酸味,易溶于水,不适宜在高温和碱性条件下加工。
生理功能:1、解酒护肝:维生素C具有促进机体排泄血液中酒精的作用。研究证实,口服维生素C剂量越大酒精排泄越快,1次口服500毫克维生素C,在1小时内酒精排泄50%以上。另外,维生素C能增强肝脏功能,起到保护肝的作用。另据报道,维生素C能分解酒精,可护胃益脾,能有效减轻酒精对胃黏膜的刺激和损伤。
2、增强免疫功能,抗感冒:维生素C能促进前列腺和淋巴液分泌,使机体产生干扰素和抗毒素,从而起到免疫和抗病毒作用,提高对机体组织的控制能力,有助于合成调节淋巴细胞的前列腺素。美国研究表明,每天1克左右的维生素C可使感冒下降45%,病程缩短60%,维生素C沟通呼吸道器官和促进血液循环,抗呼吸道感染,增强机体需要的氧,减少感冒发生。另据报道,维生素C能帮助杀灭人体病毒,因为它可以干扰病毒侵害细胞,激活白细胞,增强白细胞对病毒的吞噬能力,杀死病毒,从而增强人体免疫力,使人体免受病毒的侵害。感冒病人的白细胞中维生素C含量明显下降。
3、降血压:研究表明,维生素C具有防治高血压的作用,血液中维生素C含量越高的人,其动脉的血压越低。维生素C降血压的作用机理在于保障体内氧化物的供应,氧化物的作用是使血管保持松驰状态,从而是血压稳定。英国科学家对641名成年人血液进行化验后发现,血液中的维生素C含量越高的人,其动脉血压越低。研究认为,维生素有助于扩张血管。而大剂量维生素C可使胆固醇氧化为胆酸排出体外,改善血液循环,降低血压。
综上所述,本产品具有解酒醒酒,保护肝脏,降血压,增强免疫力等功能。
制作工艺:1、调配混合:先将配方中的原料按照物理特性混合。
2、溶解搅拌:将混合的原料溶解在温水中并充分搅拌均匀。
3、过滤:将溶解搅拌均匀的溶液送入过滤机进行过滤。
4、灌装封盖:将过滤后的溶液送入灌装机进行灌装并封盖。
5、杀菌:将灌装封盖的溶液放入80—90℃水中杀菌15分钟。
6、检验包装:将杀菌后的饮料,检验合格,成为正式产品。
调配混合工序是根据配料的物理特性分别混合的过程。溶解搅拌工序是将混合后的配料充分溶解,搅拌均匀的过程。过滤工序是为了除去溶液中的杂质和颗粒物。灌装工序是将过滤后的溶液灌装于饮料瓶中,并封盖的过程。杀菌工序是为了杀死饮料中的微生物和其他有害物质,以保证饮料品质和延长货架期的过程。检验包装工序是将杀菌后的饮料检验合格,包装成为正式产品。
六、质量标准:
1、理化指标:
2、服用方法:酒后服用500ml
七、具体实施方式
实施例:取醒酒肽60千克,谷胱甘肽4千克,y—氨基丁酸8千克,蜂蜜10千克,维生素C5千克,维生素B60.5千克,辅料混合,溶解于50℃的热水中,充分搅拌均匀,把搅拌均匀的溶液送入过滤机过滤。将过滤后的溶液送入灌装机并封盖。将灌装好的饮料在80—90℃水中杀菌15分钟。再将杀菌后的饮料检验合格包装成为正式产品。
Claims (2)
1.多肽解酒醒酒饮料的制作工艺为:调配混合、溶解搅拌、过滤、灌装封盖、杀菌、检验包装成为正式产品。
2.工艺条件为:醒酒肽60千克、谷胱甘肽4千克、y—氨基丁酸8千克、蜂蜜10千克、维生素C5千克、维生素B60.5千克、辅料混合,溶解于50℃的热水中,并充分搅拌均匀,把搅拌均匀的溶液送入过滤机进行过滤,将过滤后的溶液送入灌装机灌装并封盖,将灌装后的饮料在90℃的水中杀菌15分钟,再将杀菌后的饮料检验合格,包装成为正式产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110165891A CN102302147A (zh) | 2011-06-11 | 2011-06-11 | 多肽解酒醒酒饮料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110165891A CN102302147A (zh) | 2011-06-11 | 2011-06-11 | 多肽解酒醒酒饮料 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102302147A true CN102302147A (zh) | 2012-01-04 |
Family
ID=45376143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110165891A Pending CN102302147A (zh) | 2011-06-11 | 2011-06-11 | 多肽解酒醒酒饮料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102302147A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106616107A (zh) * | 2016-10-21 | 2017-05-10 | 孙克胜 | 一种解酒、保健、补充能量的饮料 |
CN110150574A (zh) * | 2019-06-05 | 2019-08-23 | 江西煌上煌集团食品股份有限公司 | 一种解酒鸭脚的加工方法 |
-
2011
- 2011-06-11 CN CN201110165891A patent/CN102302147A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106616107A (zh) * | 2016-10-21 | 2017-05-10 | 孙克胜 | 一种解酒、保健、补充能量的饮料 |
CN110150574A (zh) * | 2019-06-05 | 2019-08-23 | 江西煌上煌集团食品股份有限公司 | 一种解酒鸭脚的加工方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103653147B (zh) | 一种小麦肽抗疲劳保健饮料及其制备方法 | |
CN101700081B (zh) | 一种含有玫瑰花油的新型调和油的制备方法 | |
CN107223986A (zh) | 一种富硒多肽保健品及其制备方法 | |
CN1947600A (zh) | 防晒美容饮料 | |
CN102948483A (zh) | 一种降血脂奶粉及其制备方法 | |
CN106085763A (zh) | 一种保健酒及其制备方法 | |
PT102430A (pt) | Metodo aditivo de producao de agua potavel e de bebidas padronizadas a partir de agua (destilada ou desmineralizada) e de bebidas, para perfis de saude | |
CN107164446A (zh) | 鹿血肽的制备方法及其抗疲劳作用 | |
KR101186107B1 (ko) | 노루궁뎅이버섯과 은이버섯 추출물이 함유된 숙취해소용 식음료 조성물, 및 그 제조방법 | |
CN102302147A (zh) | 多肽解酒醒酒饮料 | |
CN1883286A (zh) | 一种茶奶及其制备方法 | |
CN109601967A (zh) | 一种高虾青素含量低脂肪比例蛋黄酱的制造方法 | |
CN101248871A (zh) | 含有玉物质成分的降血糖、降血压、降血脂生物食品 | |
CN103141603A (zh) | 糙米茶及其制作方法 | |
CN101983721B (zh) | 具有抗疲劳、补钙功能的苁蓉钙组合物 | |
CN1117561C (zh) | 复合钙制剂及其制备方法和用途 | |
KR20110123191A (ko) | 흑마늘을 이용한 “기능성음료”의 제조방법 | |
CN101331948A (zh) | 一种含辅酶q10和螺旋藻的复合保健品 | |
CN1204057C (zh) | 一种多元素矿物水及其制备方法 | |
CN102948733B (zh) | 一种特殊食用生命营养液的生产方法和配方 | |
CN101659919B (zh) | 一种多维果醋及其制备方法 | |
CN1631239B (zh) | 含有来源于米曲霉有机硒的酱油及其制备方法 | |
KR20030083500A (ko) | 비타민 d가 강화된 장류 및 이의 제조방법 | |
CN1386442A (zh) | 木立芦荟果汁饮料 | |
CN109757582A (zh) | 改善良性前列腺增生症状的营养食品配方 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120104 |